BNP Paribas Asset Management
PCRX icon

BNP Paribas Asset Management’s Pacira BioSciences PCRX Stock Holding History

BNP Paribas Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.82M Sell
111,263
-6,631
-6% -$157K ﹤0.01% 1044
2026
Q1 		$2.66M Buy
117,894
+99
+0.1% +$2.2K ﹤0.01% 1013
2025
Q4 		$3.05M Buy
117,795
+117,369
+27,551% +$2.79M ﹤0.01% 964
2025
Q3 		$11K Hold
426
– – ﹤0.01% 1609
2025
Q2 		$10K Buy
+426
New +$10.7K ﹤0.01% 1779

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Asset Management's PCRX Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Pacira BioSciences (PCRX) stake by 5.6% in Q2 2026, selling an estimated $157K and leaving 111,263 shares worth $2.82M. The position accounts for ﹤0.01% of the portfolio, ranked #1044.

BNP Paribas Asset Management first reported a position in PCRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $3.05M in Q4 2025. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • BNP Paribas Asset Management held 111,263 shares of Pacira BioSciences worth $2.82M as of Q2 2026.
  • BNP Paribas Asset Management sold 6,631 Pacira BioSciences shares in Q2 2026, an estimated $157K.
  • Pacira BioSciences made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1044 holding.
  • BNP Paribas Asset Management first reported a position in Pacira BioSciences in Q2 2025 and has held it in 5 quarters since.
  • BNP Paribas Asset Management's Pacira BioSciences position peaked at $3.05M in Q4 2025.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.